Parenteral nutrition is the medical term for infusing a specialized form of food through a vein (intravenously). The goal of the treatment is to cure or prevent malnutrition.
Parenteral nutrition provides liquid nutrients, including carbohydrates, proteins, fats, vitamins, minerals, and electrolytes. Some people use parenteral nutrition to feed various vitamin or protein supplements through a tube placed into the stomach or small bowel.
The global parenteral nutrition market is estimated to be valued at US$ 4,133.6 Mn in 2021, and is expected to exhibit a CAGR of 5.2 % over the forecast period (2021-2028).
Figure 1: Global Parenteral Nutrition Market Share (%) Analysis, By Nutrition Type, 2021
The increasing prevalence of malnutrition among children is expected to drive growth of the market over the forecast period.
The emerging prevalence of malnutrition among children is expected to bolster the growth of global parenteral nutrition market. For instance, according to the article published by World Health Organization, on June 9, 2021, and United Nations Children’s Fund (UNICEF), 2020, globally, 1.9 billion adults are overweight or obese, while 462 million adults are underweight. Moreover, according to the same source, globally, in 2020, it was reported that 149 million children, under the age of five, were estimated to be stunted, 45 million were estimated to be wasted, and 38.9 million were overweight or obese and around 45% of deaths among children, under the age of five years, occur mostly due to under nutrition.
Rising Government Initiatives and Issuance of New Guidelines for Parenteral Nutrition
The rising number of government initiatives focused on medical nutrition are expected to boost the global parenteral nutrition market growth during the forecast period. For instance, in October 2015, the National Association of Nutrition and Aging Services Programs (NANASP), announced an increase in the two-year budget agreement starting in October 2015, and ending in September 2017. Under the Older Americans Act (OAA), US$ 83.7 billion for the Supplemental Nutrition Assistance Program (SNAP) was allocated by the direction of former president of the U.S., Mr. Barack Obama.
| Report Coverage | Details | ||
|---|---|---|---|
| Base Year: | 2020 | Market Size in 2021: | US$ 4,133.6 Mn |
| Historical Data for: | 2017 to 2020 | Forecast Period: | 2021 to 2028 |
| Forecast Period 2021 to 2028 CAGR: | 5.2 % | 2028 Value Projection: | US$ 5,879.0 Mn |
| Geographies covered: |
|
||
| Segments covered: |
|
||
| Companies covered: |
B. Braun Melsungen AG, Fresenius Kabi AG, Baxter International Inc., Otsuka Pharmaceutical India Pvt. Ltd., Pfizer, Inc., Grifols, S.A., JW Pharmaceutical, Aculife Healthcare, Kelun, American Regent Inc., and Eurolife Healthcare Pvt. Ltd. |
||
| Growth Drivers: |
|
||
| Restraints & Challenges: |
|
||
Restraint- Global Parenteral Nutrition Market
Lack of awareness regarding healthcare, diet, and proper nutrition in low and middle income economies such as Africa and Asia Pacific is a major factor hampering the growth of the global parenteral nutrition market. There is low awareness regarding nutritional products and diseases associated with nutritional deficiencies in rural areas of low and middle income economies in Africa and Asia Pacific due to lack of healthcare professionals. For instance, according to data published by the National Center for Biotechnology Information in March 2020, African countries have around 2.3 healthcare workers per 1,000 population.
Impact of COVID-19 on Demand and Supply of Parenteral Nutrition
The COVID-19 pandemic and lockdown in various countries across the globe has impacted the financial status of businesses across all sectors including private healthcare sector. The COVID-19 pandemic has impacted the entire supply chain of the healthcare industry mainly due to strict lockdown in several regions. The COVID-19 pandemic has affected the economy of various regions across the globe in three main ways; 1) by directly affecting the production and demand; 2) by creating disruptions in distribution channels; and 3) through its financial impact on companies and financial markets. Several countries such as Thailand, Indonesia, and Singapore are facing problems with regards to transportation and distribution of healthcare products.
The regulatory authorities are updating the guidelines for the mode of providing the nutrition to the COVID-19 patients. This is expected to slightly increase the growth of the global parenteral nutrition market over the forecast period. For instance, in March 2020, Republic of Kenya Ministry of Health, released some guidelines on nutrition management of COVID-19 for the health workers in COVID-19 treatment and isolation centers. The guidance document included following recommendations for the hospital i.e. parenteral or enteral feeding during COVID-19:-
Global Parenteral Nutrition Market – Regional Analysis
On the basis of region, the global parenteral nutrition market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa.
North America is expected to hold dominant position in the global parenteral nutrition market over the forecast period, owing to the increasing number of product launches or approvals. For instance, in December 2018, the U.S. Food and Drug Administration (FDA) approved Omegaven (fish oil triglycerides), an injectable emulsion developed by Fresenius Kabi, a global health care company, for intravenous use as a source of calories and fatty acids for pediatric patients with parenteral nutrition-associated cholestasis (PNAC). Omegaven will address the need for an alternative parenteral source of fatty acids.
Moreover, due to business expansion by investing in manufacturing units by market players, Europe is expected to witness a significant growth in global parenteral nutrition market over the forecast period. For instance, in February 2021, Fresenius Kabi, a global healthcare company, announced their plans to expand its Austrian facilities. The company will invest more than US$ 69.4 million through 2023 to expand capacity and upgrade infrastructure at its production plant in Graz and packaging center nearby Werndorf, Europe.
Figure 2: Global Parenteral Nutrition Market Value (US$ Mn), by Region, 2021
Global Parenteral Nutrition Market – Competitive Landscape
Major players operating in the global parenteral nutrition market include B. Braun Melsungen AG, Fresenius Kabi AG, Baxter International Inc., Otsuka Pharmaceutical India Pvt. Ltd., Pfizer, Inc., Grifols, S.A., JW Pharmaceutical, Aculife Healthcare, Kelun, American Regent Inc., and Eurolife Healthcare Pvt. Ltd.
Parenteral nutrition, also known as intravenous feeding, is a method of delivering nutrition to the human body via veins. This procedure is known as total parenteral nutrition (TPN) or peripheral parenteral nutrition (PPN) depending on which vein is used. TPN involves inserting a catheter into a large vein called the superior vena cava, which leads to the heart. A port, such as a needleless access port, may also be implanted by the healthcare provider to facilitate intravenous feeding. PPN may be recommended by the doctor for temporary nutritional needs. Instead of a central line threaded into the superior vena cava, this type of intravenous feeding employs a standard peripheral intravenous line.
Market Dynamics
Market players are focused on product launches or approvals, this could contribute to the growth of the global parenteral nutrition market over the forecast period. For instance, in September 2020, Baxter International Inc., a global leader in clinical nutrition, announced that the U.S. Food and Drug Administration (FDA) approved the new formulations of Clinimix (amino acids in dextrose) injections and Clinimix E (amino acids with electrolytes in dextrose and calcium) injections. These new Clinimix formulations contain up to 80 g/L of amino acids, the highest protein in any multi-chamber bag available in the U.S.
Market players are focused on launching manufacturing facilities for parenteral nutrition. This is expected to drive the market growth over the forecast period. For instance, in July 2018, Pfizer expanded its U.S. manufacturing capacity by investing US$ 465 million to build a technically advanced sterile injectable pharmaceutical production facility. This U.S. investment strengthened Pfizer’s capability to produce and supply critical, life-saving injectable medicines for patients across the world.
Market players focused on initiative and programs related to healthcare nutrition is expected to propel the growth of the global parenteral nutrition market. For instance, in 2017, B. Braun Medical Inc., presented its new parenteral nutrition program – PN360 at the American Society for Parenteral and Enteral Nutrition (A.S.P.E.N.) Clinical Nutrition Week. The program is designed to improve neonatal, pediatric, and adult patient outcomes.
Key features of the study:
Detailed Segmentation:
“*” marked represents similar segmentation in other categories in the respective section.
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients